loading...| Preferred Name | fostriecin | |
| Synonyms |
CI 920 PD-110,161 CI-920 PD 110161 2H-Pyran-2-one, 5,6-dihydro-6-(3,6,13-trihydroxy-3-methyl-4-(phosphonooxy)-1,7,9,11-tridecatetraenyl)-, trans- |
|
| ID |
http://purl.bioontology.org/ontology/MESH/C040313 |
|
| altLabel |
CI 920 PD-110,161 CI-920 PD 110161 2H-Pyran-2-one, 5,6-dihydro-6-(3,6,13-trihydroxy-3-methyl-4-(phosphonooxy)-1,7,9,11-tridecatetraenyl)-, trans- |
|
| cui |
C0135713 C0118175 C0109728 |
|
| HM |
D011753 D011090 |
|
| II |
D010749/Q000037 |
|
| Inverse of RB |
ZO1648L551 |
|
| isa | ||
| Mapped to | ||
| MDA |
19840312 |
|
| MeSH Frequency |
106 |
|
| MMR |
20121105 |
|
| notation |
C040313 |
|
| PA |
D004791 |
|
| PI |
*Alkenes (2009-2010) |
|
| prefLabel |
fostriecin |
|
| RR |
87810-56-8 (fostriecin) |
|
| SC |
1 |
|
| Scope Statement |
compound contains a conjugated triene and an unsaturated lactone; from Streptomyces pulveraceus; structure given in second source |
|
| SRC |
J Antibiot (Tokyo) 1983;36(12):1601 J Antibiot (Tokyo) 1983;36(12):1595 |
|
| TERMUI |
T150120 T150119 T150116 T150118 T150117 |
|
| TH |
FDA SRS (2013) INN (19XX) USAN (1984) NLM (1984) |
|
| tui |
T109 T121 |